Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Helena Mora-Jensen"'
Autor:
Nan Hu, Helena Mora-Jensen, Kim Theilgaard-Mönch, Berber Doornbos-van der Meer, Minke G Huitema, Coen A Stegeman, Peter Heeringa, Cees G M Kallenberg, Johanna Westra
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e99671 (2014)
ObjectiveDifferential gene expression in CD177+ and CD177- neutrophils was investigated, in order to detect possible differences in neutrophil function which could be related to the pathogenesis of ANCA-associated Vasculitides (AAV).MethodsNeutrophil
Externí odkaz:
https://doaj.org/article/b6660195b8d34d87be429bd05cd7e26c
Autor:
Jennifer A. Woyach, Adrian Wiestner, Brian J. Lannutti, Amy J. Johnson, Roger Ulrich, Allard Kaptein, Raquel Izumi, John C. Byrd, Todd Covey, Dolors Colomer, Bonnie K. Harrington, Fabienne McClanahan, Lisa L. Smith, Rose Mantel, Fanny Krantz, Michael Gulrajani, Helena Mora-Jensen, Carsten U. Niemann, Arnau Montraveta, Sarah E.M. Herman
Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK. We sought to evaluate the antitumor effects of acalabrutinib treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e3ca1183f3e1691c0fae26104477a98
https://doi.org/10.1158/1078-0432.c.6525228.v1
https://doi.org/10.1158/1078-0432.c.6525228.v1
Autor:
Jennifer A. Woyach, Adrian Wiestner, Brian J. Lannutti, Amy J. Johnson, Roger Ulrich, Allard Kaptein, Raquel Izumi, John C. Byrd, Todd Covey, Dolors Colomer, Bonnie K. Harrington, Fabienne McClanahan, Lisa L. Smith, Rose Mantel, Fanny Krantz, Michael Gulrajani, Helena Mora-Jensen, Carsten U. Niemann, Arnau Montraveta, Sarah E.M. Herman
Supplementary Table S1. Kinase selectivity of acalabrutinib as assessed by DiscoveRX KinomeScan screening.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87cd29d20b722cbec12775285af50743
https://doi.org/10.1158/1078-0432.22462842
https://doi.org/10.1158/1078-0432.22462842
Autor:
Jennifer A. Woyach, Adrian Wiestner, Brian J. Lannutti, Amy J. Johnson, Roger Ulrich, Allard Kaptein, Raquel Izumi, John C. Byrd, Todd Covey, Dolors Colomer, Bonnie K. Harrington, Fabienne McClanahan, Lisa L. Smith, Rose Mantel, Fanny Krantz, Michael Gulrajani, Helena Mora-Jensen, Carsten U. Niemann, Arnau Montraveta, Sarah E.M. Herman
Supplementary Figure S5: Acalabrutinib demonstrates similar changes in proliferation and tumor burden in the CLL xenograft mouse model as ibrutinib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09c6b24397ba4d6b61ecbea462928663
https://doi.org/10.1158/1078-0432.22462839
https://doi.org/10.1158/1078-0432.22462839
Autor:
Jennifer A. Woyach, Adrian Wiestner, Brian J. Lannutti, Amy J. Johnson, Roger Ulrich, Allard Kaptein, Raquel Izumi, John C. Byrd, Todd Covey, Dolors Colomer, Bonnie K. Harrington, Fabienne McClanahan, Lisa L. Smith, Rose Mantel, Fanny Krantz, Michael Gulrajani, Helena Mora-Jensen, Carsten U. Niemann, Arnau Montraveta, Sarah E.M. Herman
Supplementary Figure S1: Acalabrutinib is a more potent BCR-inhibitor than ibrutinib in vivo at 1mg/kg and 3mg/kg. Supplementary Figure S2: In vivo gating strategy for murine cells. Supplementary Figure S3: In vivo acalabrutinib treatment inhibits BC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84e9dec56789480c721bd888084a7d11
https://doi.org/10.1158/1078-0432.22462836.v1
https://doi.org/10.1158/1078-0432.22462836.v1
Publikováno v:
HLAREFERENCES. 98(1)
HLA-DPA1*01:46 differs from HLA-DPA1*01:03 in exon 2 at amino acid 85; Aspartate to Asparagine substitution.
Autor:
Helena Mora-Jensen, Anne Werner Hauge, Kit P. Lund, Søren Schwartz Sørensen, Frank Eriksson, Helle Bruunsgaard
Publikováno v:
Web of Science
The importance of the human leukocyte antigen (HLA) system in kidney transplantation is well-known, but it remains unexplored if patient HLA antigens constitute independent risk factors in complications after transplantation. We hypothesized that spe
Autor:
Raquel Izumi, Helena Mora-Jensen, Carsten Utoft Niemann, Adrian Wiestner, Eman L. Dadashian, Todd Covey, Nicholas Chiorazzi, Shih-Shih Chen, Brian Lannutti, Roger G. Ulrich, Fanny Krantz, Sarah E. M. Herman
Publikováno v:
Clinical Cancer Research. 23:5814-5823
Purpose: Targeting the B-cell receptor (BCR) pathway with inhibitors of Bruton tyrosine kinase (BTK) and PI3Kδ is highly effective for the treatment of chronic lymphocytic leukemia (CLL). However, deep remissions are uncommon, and drug resistance wi
Autor:
Helena Mora-Jensen, Bo T. Porse, A. S. Roug, Mette K. Andersen, Lars Bullinger, Johan Jendholm, Nicolas Rapin, Niels Borregaard, Kim Theilgaard-Mönch, Frederik Otzen Bagger, Ole Winther
Publikováno v:
Leukemia. 29:1785-1789
Autor:
Fanny Krantz, Dolors Colomer, Raquel Izumi, Jennifer A. Woyach, Bonnie K. Harrington, Arnau Montraveta, Sarah E. M. Herman, Carsten Utoft Niemann, Fabienne McClanahan, Amy J. Johnson, Lisa L. Smith, Todd Covey, Brian J. Lannutti, Roger G. Ulrich, Helena Mora-Jensen, Rose Mantel, Adrian Wiestner, Allard Kaptein, Michael Gulrajani, John C. Byrd
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(11)
Purpose: Acalabrutinib (ACP-196) is a novel, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor, which binds covalently to Cys481 in the ATP-binding pocket of BTK. We sought to evaluate the antitumor effects of acalabrutinib treatmen